Rituximab therapy in ROHHAD(NET) syndrome.

Katherine A C HawtonRainer DoffingerAthimalaipet V RamananSimon C Langton HewerHazel J EvansDinesh GiriJulian P Hamilton Shield

Published in: Journal of pediatric endocrinology & metabolism : JPEM (2022)

This response possibly reflects an underlying, immune-inflammatory pathology driving excess adiposity in this condition. Potentially, other aspects of ROHHAD(NET) may be mediated through autoimmune dysregulation in which case rituximab may provide benefits for prognosis and survival.

Keyphrases

diffuse large b cell lymphoma
chronic lymphocytic leukemia
hodgkin lymphoma
multiple sclerosis
insulin resistance
oxidative stress
case report
stem cells
drug induced
cell therapy
bone marrow
smoking cessation